ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Risk of Tumor Recurrence, Functional Decline, and Metastatic Disease of Renal Transplant in Recipients with Hereditary Kidney Cancer: A Case Series

M. Antony, A. Chaurasia, N. Gopal, Z. Kozel, M. Linehan, M. Ball

Urologic Oncology Branch, National Cancer Institute, Bethesda, MD

Meeting: 2022 American Transplant Congress

Abstract number: 1419

Keywords: Genomics, Graft survival, Malignancy, Renal failure

Topic: Clinical Science » Kidney » 49 - Recurrent Kidney Disease & Genetics

Session Information

Session Name: Recurrent Kidney Disease & Genetics

Session Type: Poster Abstract

Date: Monday, June 6, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Von Hippel-Lindau disease is a hereditary cancer syndrome characterized by bilateral, multifocal renal tumors and cysts. Advancements in nephron-sparing surgeries have improved functional and oncologic outcomes in these patients. If parenchyma cannot be salvaged, renal replacement therapy is indicated. This case series aims to examine outcomes of patients who have undergone renal transplant secondary to surgical loss their kidneys.

*Methods: We identified 8 VHL patients in an institutionally maintained database at the NCI undergoing renal transplant from 1989 to 2021. Transplants were conducted at an outside institution for all patients, and charts were reviewed for surgical and transplant outcomes. Graft time was defined as years of graft function until failure or patient death.

*Results: Median partial nephrectomies prior to radical nephrectomy was 2 (IQR: 1.25-3.5). Three patients underwent bilateral nephrectomy with no prior partial nephrectomy. At time of transplant, seven patients had no native tissue found on imaging of graft, while one patient had partial native kidney. Three patients had data available for donor kidney source, with two having cadaveric donors, and one with a living donor. All patients exhibited signs of renal failure at time of transplant, with complications such as uremic cardiomyopathy (n=1) and electrolyte derangements (n=4). Patients spent a median of 3.5 years on dialysis, consistent with the national average of ‘time on transplant list’ at 3.6 years. Median age at transplant was 28, ranging from 23 to 67. Median graft time was 5 years, with a graft range of 1 to 20 years. All the patients were prescribed immunosuppressive therapy with prednisolone and immunomodulators, most commonly tacrolimus. All patients tolerated immunosuppression, but one patient who developed systemic fungal infection and died. One patient developed an acute graft rejection, diagnosed on allograft biopsy months after the transplant. One patient died during partial nephrectomy of native kidney. None of the subjects developed tumor recurrence or metastatic disease on imaging.

*Conclusions: Given the operative challenges posed by VHL, transplant is a viable option for patients with limited functional kidney parenchyma. Though renal transplant is minimally utilized in this institutional cohort, this case series suggests that risk of disease recurrence in graft and development of metastasis is minimal. This demonstrates utility of renal transplant in management of end-stage renal disease within the VHL patient population.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Antony M, Chaurasia A, Gopal N, Kozel Z, Linehan M, Ball M. Risk of Tumor Recurrence, Functional Decline, and Metastatic Disease of Renal Transplant in Recipients with Hereditary Kidney Cancer: A Case Series [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/risk-of-tumor-recurrence-functional-decline-and-metastatic-disease-of-renal-transplant-in-recipients-with-hereditary-kidney-cancer-a-case-series/. Accessed May 28, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences